Repligen Corporation (RGEN) has a consensus analyst rating of Buy, based on 23 analysts covering the stock. Of those, 20 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for RGEN is $183.00, representing a +39.7% upside from the current price of $131.03. Price targets range from a low of $160.00 to a high of $200.00.
